Baxter International Inc. Form 8-K Filing

Baxter International Inc. filed a Form 8-K on April 30, 2026, reporting its first-quarter 2026 financial results. The company reported sales from continuing operations of $2.7 billion, a 3% increase on a reported basis and a 1% decrease on an organic basis. U.S. GAAP diluted EPS from continuing operations was ($0.03), while adjusted diluted EPS from continuing operations was $0.36. Baxter reiterated its full-year 2026 financial outlook, projecting reported sales growth of flat to 1% and organic sales growth of approximately flat. The company also announced a quarterly cash dividend of $0.01 per share, payable on July 1, 2026. The filing detailed segment results, with Medical Products & Therapies sales increasing 2% reported and decreasing 2% organic, Healthcare Systems & Technologies sales flat reported and decreasing 2% organic, and Pharmaceuticals sales increasing 7% reported and 1% organic. Baxter highlighted strategic initiatives, including product introductions and the expansion of its continuous improvement system.